Colon Adenocarcinoma, ERBB2 Gene Amplification, Rectal Adenocarcinoma, Recurrent Colon Carcinoma, Recurrent Rectal Carcinoma, Stage IIIA Colon Cancer AJCC v7, Stage IIIA Rectal Cancer AJCC v7, Stage IIIB Colon Cancer AJCC v7, Stage IIIB Rectal Cancer AJCC v7, Stage IIIC Colon Cancer AJCC v7, Stage III Colon Cancer AJCC v7, Stage IIIC Rectal Cancer AJCC v7, Stage III Rectal Cancer AJCC v7, Stage IVA Colon Cancer AJCC v7, Stage IVA Rectal Cancer AJCC v7, Stage IVB Colon Cancer AJCC v7, Stage IVB Rectal Cancer AJCC v7, Stage IV Colon Cancer AJCC v7, Stage IV Rectal Cancer AJCC v7
Conditions
Brief summary
This randomized phase II trial studies how well trastuzumab and pertuzumab work compared to cetuximab and irinotecan hydrochloride in treating patients with HER2/neu amplified colorectal cancer that has spread from where it started to other places in the body and cannot be removed by surgery. Monoclonal antibodies, such as trastuzumab and pertuzumab, may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as cetuximab and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving trastuzumab and pertuzumab may work better compared to cetuximab and irinotecan hydrochloride in treating patients with colorectal cancer.
Detailed description
PRIMARY OBJECTIVES: I. To evaluate the efficacy of trastuzumab and pertuzumab (TP) (Arm 1) in HER-2 amplified metastatic colorectal cancer (mCRC) by comparing progression-free survival (PFS) on TP compared to control arm (Arm 2) of cetuximab and irinotecan hydrochloride (irinotecan) (CETIRI). SECONDARY OBJECTIVES: I. To evaluate the overall response rate (ORR), including confirmed complete and partial response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, in treatment Arms 1 and 2. II. To evaluate the overall survival (OS) in treatment Arms 1 and 2. III. To evaluate the safety and toxicity of TP compared to CETIRI. TERTIARY OBJECTIVES: I. To estimate the rates of PFS, OS, and ORR in patients who crossover to TP (Arm 3) after disease progression on CETIRI. II. To bank images for future retrospective analysis. III. To evaluate if HER-2/centromeric probe (CEP17) signal ratio and HER-2 gene copy number (GCN) are predictive of clinical efficacy for patients receiving TP versus CETIRI. IV. To bank tissue and blood samples for other future correlative studies from patients enrolled on the study. OUTLINE: Patients with HER2 gene amplification are randomized to 1 of 2 arms. ARM I: Patients receive pertuzumab intravenously (IV) over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. ARM II: Patients receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Patients with documented disease progression may optionally crossover to Arm I. After completion of study treatment, patients are followed up for 3 years.
Interventions
BIOLOGICALCetuximab
Given IV
DRUGIrinotecan Hydrochloride
Given IV
OTHERLaboratory Biomarker Analysis
Correlative studies
BIOLOGICALPertuzumab
Given IV
BIOLOGICALTrastuzumab
Given IV
DEVICEHER-2 testing
Central testing of HER-2 for eligibility
Sponsors
SWOG Cancer Research Network
National Cancer Institute (NCI)
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* STEP 1 INITIAL REGISTRATION: HER2 TESTING * Patients must have histologically or cytologically documented adenocarcinoma of the colon or rectum that is metastatic or locally advanced and unresectable * Mutation results: * All patients must have molecular testing performed in a Clinical Laboratory Improvement Act (CLIA) certified lab which includes which includes KRAS and NRAS gene and exon 15 of BRAF gene (BRAF V600E mutation); patients with any known activating mutation in exon 2 \[codons 12 and 13\], exon 3 \[codons 59 and 61\] and exon 4 \[codons 117 and 146\]) of KRAS/NRAS genes and in exon 15 (BRAFV600E mutation) of BRAF gene are not eligible * Patients must not have been treated with any of the following prior to step 1 initial registration: * Cetuximab, panitumumab, or any other monoclonal antibody against EGFR or inhibitor of EGFR * HER-2 targeting for treatment of colorectal cancer; patients who have received prior trastuzumab or pertuzumab for other indications such as prior history of adjuvant or neoadjuvant breast cancer treatment prior to the development of advanced colorectal cancer are eligible * Patients must not have had history of severe toxicity and intolerance to or hypersensitivity to irinotecan or any other study drug; patients must not have had a severe infusion-related reaction during any prior therapy with pertuzumab or trastuzumab * Patients must have tumor slides available for submission for HER-2 testing; HER-2 testing must be completed by the central lab prior to step 2 randomization * Patients must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines; for step 1 initial registration, the appropriate consent form is the step 1 consent form * As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * STEP 2 RANDOMIZATION * Patients must have HER-2 amplification as determined by central testing (3+ or 2+ by immunohistochemistry and HER-2 gene amplification by in situ hybridization with a ratio of HER-2 gene signals to centromere 17 signals \>= 2.0) * Patients must have measurable disease that is metastatic or locally advanced and unresectable; imaging used to assess all disease per RECIST 1.1 must have been completed within 28 days prior to step 2 randomization; all disease must be assessed and documented on the Baseline Tumor Assessment Form * Patients must have had at least one prior regimen of systemic chemotherapy for metastatic or locally advanced, unresectable disease; patients must have progressed following the most recent therapy; prior treatment with irinotecan is allowed; for patients that received adjuvant chemotherapy: prior treatment for metastatic disease is not required for patient who experienced disease recurrence during or within 6 months of completion of adjuvant chemotherapy; if the patient received one line of adjuvant treatment and had disease recurrence after 6 months of completing chemotherapy, patients will only be eligible after failing one additional line of chemotherapy used to treat the metastatic or locally advanced, unresectable disease; patients who have received \>= 3 lines of systemic chemotherapy for metastatic or locally advanced, unresectable disease are not eligible * Patients must have completed prior chemotherapy, immunotherapy, or radiation therapy at least 14 days prior to step 2 randomization and all toxicity must be resolved to Common Terminology Criteria for Adverse Events (CTCAE) version (v)4.0 grade 1 (with the exception of CTCAE v4.0 grade 2 neuropathy) prior to step 2 randomization * Brain metastases are allowed if they have been adequately treated with radiotherapy or surgery and stable for at least 30 days prior to step 2 randomization; eligible patients must be neurologically asymptomatic and without corticosteroid treatment for at least 7 days prior to step 2 randomization * Patients must have a Zubrod performance status of 0 or 1 * Patients must have a complete physical examination and medical history within 28 days prior to step 2 randomization * Absolute neutrophil count (ANC) \>= 1,500/mcL * Platelets \>= 75,000/mcL * Hemoglobin \>= 9 g/dL * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =\< 5 x institutional upper limit of normal (IULN) * Bilirubin =\< 1.5 mg/dL * Calculated creatinine clearance \> 30 ml/min within 14 days prior to step 2 randomization * Patients who have had an echocardiogram performed within 6 months prior to step 2 randomization must have ventricular ejection fraction (left ventricular ejection fraction \[LVEF\]) \>= 50% or \>= within normal limits for the institution * Patients must not have an uncontrolled intercurrent illness including, but not limited to diabetes, hypertension, severe infection, severe malnutrition, unstable angina, class III-IV New York Heart Association (NYHA) congestive heart failure, ventricular arrhythmias, active ischemic heart disease, or myocardial infarction within 6 months prior to step 2 randomization * Patients must not have any known previous or concurrent condition suggesting susceptibility to hypersensitivity or allergic reactions, including, but not limited to: known hypersensitivity to any of the study treatments or to excipients of recombinant human or humanized antibodies; patients with mild or seasonal allergies may be included after discussion with the study chairs * Patients must not be planning treatment with other systemic anti-cancer agents (e.g., chemotherapy, hormonal therapy, immunotherapy) or other treatments not part of protocol-specified anti-cancer therapy including concurrent investigational agents of any type * No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, ductal carcinoma in situ, other low grade lesions such as incidental appendix carcinoid, or any other cancer from which the patient has been disease and treatment free for two years; prostate cancer patients on active surveillance are eligible * Patients must not be pregnant or nursing; females of child-bearing potential must have a negative serum pregnancy test within 7 days prior to registration; women/men of reproductive potential must have agreed to use an effective contraceptive method while on study and for at least 7 months after the last dose of study treatment; a woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures * Patients must be given the opportunity to consent to the optional submission of tissue for future research * Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; the appropriate consent form for this registration is the step 2 consent form * STEP 2 RANDOMIZATION: As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have documented disease progression while on CETIRI (Arm 2) on this protocol; the Follow-up Tumor Assessment Form documenting disease progression must be submitted to Southwest Oncology Group (SWOG) prior to step 3 crossover registration; registration to step 3 crossover must be within 28 days of discontinuation of CETIRI protocol treatment; patients going off treatment for any other reason are not eligible * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have a Zubrod performance status of 0 or 1 * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): ANC \>= 1,500/mcL * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Platelets \>= 75,000/mcL * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Hemoglobin \>= 9 g/dL * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): AST and ALT both =\< 5 x institutional upper limit of normal (IULN) * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Bilirubin =\< 1.5 mg/dL * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Calculated creatinine clearance \> 30 ml/min within 14 days prior to step 3 crossover registration * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have left ventricular ejection fraction (LVEF) \>= 50% or \>= lower limit of normal for the institution by echocardiogram within 14 days prior to step 3 crossover registration * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must have a magnesium, potassium, calcium, sodium, bicarbonate, and chloride performed within 14 days prior to step 3 crossover registration * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines; the appropriate consent form for this registration is the step 2 consent form * STEP 3 CROSSOVER REGISTRATION (OPTIONAL): As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free Survival(PFS) | Up to 3 years post randomization | To evaluate the efficacy of trastuzumab and pertuzumab (TP) in HER-2 amplified metastatic colorectal cancer (mCRC) by comparing progression-free survival (PFS) on TP compared to control arm of cetuximab and irinotecan (CETIRI). Progression-free survival is defined as the time from date of randomization to date of first documentation of progression. Using RECIST 1.1, progression is defined as a 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed and an absolute increase of at least 0.5 cm, unequivocal progression of non-measurable disease in the opinion of the treating physician, appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration (defined as, global deterioration of health status requiring discontinuation of treatment without objective evidence of progression), or death due to any cause. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Response Rate (ORR) for TP and CETIRI Treatment Arms | From baseline, through duration of treatment (once per cycle while on treatment), and every 8 weeks after treatment until progression, up to 3 years after the last accrual to registration step 2 | To evaluate the overall response rate (ORR), including confirmed complete and partial response per RECIST 1.1, in the TP and CETIRI treatment arms. Overall response rate includes complete response(CR) and partial response(PR). Complete response is defined as complete disappearance of all target and non-target lesions and no related symptoms. Partial response is defined as a greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions for patients with at least one measurable lesion. |
| 2 Year Overall Survival (OS) for TP and CETIRI Treatment Arms | from the date of the last accrual to registration step 2 to date of death due to any cause, up to 2 years | Percentage of participants still alive 2 years after the last accrual to registration step 2. Overall survival is defined as time from date of registration to date of death due to any cause. Patients last known to be alive are censored at their last contact date. |
| Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Duration of treatment and follow-up until death or 3 years post Step 2 Randomization. | Routine toxicities were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0, and SAEs were evaluated according to CTCAE version 5.0. Only adverse events that are possibly, probably, or definitely related to study drug are reported. |
Countries
Puerto Rico, United States
Contacts
PRINCIPAL_INVESTIGATORKanwal Raghav
SWOG Cancer Research Network
Participant flow
Pre-assignment details
240 participants were screened for HER-2 amplification, 54 participant were HER-2 positive and randomized to therapy, 1 patient is not analyzable due to withdrawal of consent and refusal of protocol treatment.
Participants by arm
| Arm | Count |
|---|---|
| Trastuzumab + Pertuzumab Participants receive pertuzumab intravenously (IV) over 30-60 minutes and trastuzumab IV over 30-120 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity. | 26 |
| Cetuximab + Irinotecan Participants receive cetuximab IV over 60-120 minutes and irinotecan hydrochloride IV over 90 minutes on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity. Participants with documented disease progression may optionally crossover to Arm I. | 27 |
| Total | 53 |
Baseline characteristics
| Characteristic | Cetuximab + Irinotecan | Total | Trastuzumab + Pertuzumab |
|---|---|---|---|
| Age, Continuous | 59.1 years | 57.6 years | 56.2 years |
| HER2/CEP17 Ratio <=5 | 7 Participants | 14 Participants | 7 Participants |
| HER2/CEP17 Ratio >5 | 20 Participants | 39 Participants | 19 Participants |
| Number of Participants with Prior Use of Irinotecan No | 14 Participants | 29 Participants | 15 Participants |
| Number of Participants with Prior Use of Irinotecan Yes | 13 Participants | 24 Participants | 11 Participants |
| Race/Ethnicity, Customized Hispanic No | 25 Participants | 48 Participants | 23 Participants |
| Race/Ethnicity, Customized Hispanic Unknown | 0 Participants | 2 Participants | 2 Participants |
| Race/Ethnicity, Customized Hispanic Yes | 2 Participants | 3 Participants | 1 Participants |
| Race/Ethnicity, Customized Race Asian | 1 Participants | 5 Participants | 4 Participants |
| Race/Ethnicity, Customized Race Black | 4 Participants | 5 Participants | 1 Participants |
| Race/Ethnicity, Customized Race Unknown | 1 Participants | 3 Participants | 2 Participants |
| Race/Ethnicity, Customized Race White | 21 Participants | 40 Participants | 19 Participants |
| Sex: Female, Male Female | 13 Participants | 26 Participants | 13 Participants |
| Sex: Female, Male Male | 14 Participants | 27 Participants | 13 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 9 / 26 | 18 / 27 | 12 / 20 |
| other Total, other adverse events | 23 / 26 | 26 / 26 | 18 / 20 |
| serious Total, serious adverse events | 8 / 26 | 1 / 26 | 5 / 20 |
Outcome results
Primary
Progression-free Survival(PFS)
To evaluate the efficacy of trastuzumab and pertuzumab (TP) in HER-2 amplified metastatic colorectal cancer (mCRC) by comparing progression-free survival (PFS) on TP compared to control arm of cetuximab and irinotecan (CETIRI). Progression-free survival is defined as the time from date of randomization to date of first documentation of progression. Using RECIST 1.1, progression is defined as a 20% increase in the sum of appropriate diameters of target measurable lesions over smallest sum observed and an absolute increase of at least 0.5 cm, unequivocal progression of non-measurable disease in the opinion of the treating physician, appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration (defined as, global deterioration of health status requiring discontinuation of treatment without objective evidence of progression), or death due to any cause.
Time frame: Up to 3 years post randomization
Population: This population includes the 53 eligible and evaluable participants. 26 in the Trastuzumab + Pertuzumab arm and 27 in the Cetuximab + Irinotecan arm.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Trastuzumab + Pertuzumab | Progression-free Survival(PFS) | 4.7 Months |
| Cetuximab + Irinotecan | Progression-free Survival(PFS) | 3.7 Months |
p-value: 0.4495% CI: [0.43, 1.45]Log Rank
Secondary
2 Year Overall Survival (OS) for TP and CETIRI Treatment Arms
Percentage of participants still alive 2 years after the last accrual to registration step 2. Overall survival is defined as time from date of registration to date of death due to any cause. Patients last known to be alive are censored at their last contact date.
Time frame: from the date of the last accrual to registration step 2 to date of death due to any cause, up to 2 years
Population: This population includes the 53 eligible and evaluable participants. 26 participants in the Trastuzumab + Pertuzumab arm and 27 participants in the Cetuximab + Irinotecan arm.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Trastuzumab + Pertuzumab | 2 Year Overall Survival (OS) for TP and CETIRI Treatment Arms | 67.1 percentage of participants |
| Cetuximab + Irinotecan | 2 Year Overall Survival (OS) for TP and CETIRI Treatment Arms | 56.7 percentage of participants |
p-value: 0.17Log Rank
Secondary
Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs.
Routine toxicities were evaluated according to National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0, and SAEs were evaluated according to CTCAE version 5.0. Only adverse events that are possibly, probably, or definitely related to study drug are reported.
Time frame: Duration of treatment and follow-up until death or 3 years post Step 2 Randomization.
Population: Participants who were eligible and received at least one dose of protocol treatment.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Alkaline phosphatase increased | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Hypokalemia | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Atrial fibrillation | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Hypomagnesemia | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Abdominal pain | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Infusion related reaction | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Diarrhea | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Leukocytosis | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Anemia | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Lymphocyte count decreased | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Dyspnea | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Rash acneiform | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Alanine aminotransferase increased | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Rash maculo-papular | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Fatigue | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Thromboembolic event | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Anorexia | 0 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Vomiting | 1 Participants |
| Trastuzumab + Pertuzumab | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Gastrointestinal disorders - Other, specify | 0 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Vomiting | 1 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Abdominal pain | 0 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Alkaline phosphatase increased | 0 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Anemia | 1 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Anorexia | 1 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Atrial fibrillation | 0 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Diarrhea | 2 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Dyspnea | 0 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Fatigue | 2 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Gastrointestinal disorders - Other, specify | 2 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Hypokalemia | 1 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Hypomagnesemia | 1 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Infusion related reaction | 0 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Leukocytosis | 1 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Lymphocyte count decreased | 0 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Rash acneiform | 3 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Rash maculo-papular | 2 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Thromboembolic event | 1 Participants |
| Cetuximab + Irinotecan | Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs. | Alanine aminotransferase increased | 0 Participants |
Secondary
Overall Response Rate (ORR) for TP and CETIRI Treatment Arms
To evaluate the overall response rate (ORR), including confirmed complete and partial response per RECIST 1.1, in the TP and CETIRI treatment arms. Overall response rate includes complete response(CR) and partial response(PR). Complete response is defined as complete disappearance of all target and non-target lesions and no related symptoms. Partial response is defined as a greater than or equal to 30% decrease under baseline of the sum of appropriate diameters of all target measurable lesions for patients with at least one measurable lesion.
Time frame: From baseline, through duration of treatment (once per cycle while on treatment), and every 8 weeks after treatment until progression, up to 3 years after the last accrual to registration step 2
Population: This population includes the 53 eligible and evaluable participants. 26 participants in the Trastuzumab + Pertuzumab arm and 27 participants in the Cetuximab + Irinotecan arm.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Trastuzumab + Pertuzumab | Overall Response Rate (ORR) for TP and CETIRI Treatment Arms | 9 Participants |
| Cetuximab + Irinotecan | Overall Response Rate (ORR) for TP and CETIRI Treatment Arms | 7 Participants |